Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Status Completed

Clinical Trial Summary

This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

Clinical Trial Description

This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04541329
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Completed
Phase	Phase 4
Start date	September 16, 2020
Completion date	January 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03669757` - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis	Phase 1
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Completed	`NCT03584360` - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin	Phase 2
Recruiting	`NCT04994951` - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.	Phase 2
Completed	`NCT02888236` - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris	Phase 2
Completed	`NCT02533973` - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population	Phase 4
Completed	`NCT02193815` - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	Phase 1
Completed	`NCT01946386` - A Vasoconstriction Study With LEO 90100	Phase 1
Completed	`NCT02004847` - Blue Light for Treating Psoriasis Vulgaris	N/A
Recruiting	`NCT01443338` - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2	Phase 4
Completed	`NCT01188928` - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)	Phase 3
Completed	`NCT00764751` - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris	Phase 2
Completed	`NCT00236171` - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test	N/A
Completed	`NCT06064084` - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting	`NCT06398106` - Proactive TDM Versus Standard Use of Biologics in Psoriasis	Phase 4
Recruiting	`NCT05390515` - Psoriatic Immune Response to Tildrakizumab	Phase 4
Recruiting	`NCT05892640` - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis	N/A
Recruiting	`NCT04950218` - The Psoriasis Echo Study
Completed	`NCT05184348` - Plexin B2 Gene Expression and Polymorphisms in Psoriasis	Phase 1
Recruiting	`NCT04394936` - An Explorative Psoriasis Biomarker Study	N/A